Aoki N, Moroi M, Matsuda M, Tachiya K
J Clin Invest. 1977 Aug;60(2):361-9. doi: 10.1172/JCI108784.
Human plasma alpha2-plasmin inhibitor in fibrinolytic states was studied using immunochemical methods and radioiodinated plasminogen. The concentration and activity of plasma alpha2-plasmin inhibitor decreased when urokinase was added to plasma in vitro or infused intravenously in man. The decrease was associated with the appearance of plasmin-alpha2-plasmin inhibitor complex which subsequently disappeared from the circulation in a short time. A decrease of other major inhibitors, such as alpha2-macroglobulin and alpha1-antitrypsin, was not observed when the amount of urokinase added or infused was relatively small, and conversion of plasminogen to plasmin was not extensive. The formation of plasmin-alpha2-macroglobulin complex was observed only when plasma plasminogen was activated with a larger amount of urokinase, and after most of the alpha2-plasmin inhibitor was consumed by forming complexes with plasmin. The formation of plasmin-alpha1-antitrypsin complex was not observed even in the highly activated plasma unless exogenous plasmin was added to the plasma. alpha2-Plasmin inhibitor was the only inhibitor of which the concentration in plasma was significantly decreased in patients with disseminated intravascular coagulation and fibrinolysis among the major plasmin inhibitors in plasma. The most reactive inhibitor for regulating plasma fibrinolysis very likely is alpha2-plasmin inhibitor.
采用免疫化学方法和放射性碘化纤维蛋白溶酶原对纤维蛋白溶解状态下的人血浆α2 - 纤维蛋白溶酶抑制剂进行了研究。当在体外向血浆中加入尿激酶或对人静脉输注尿激酶时，血浆α2 - 纤维蛋白溶酶抑制剂的浓度和活性会降低。这种降低与纤维蛋白溶酶-α2 - 纤维蛋白溶酶抑制剂复合物的出现有关，该复合物随后在短时间内从循环中消失。当加入或输注的尿激酶量相对较小时，未观察到其他主要抑制剂如α2 - 巨球蛋白和α1 - 抗胰蛋白酶的减少，并且纤维蛋白溶酶原向纤维蛋白溶酶的转化也不广泛。仅当用大量尿激酶激活血浆纤维蛋白溶酶原，且大部分α2 - 纤维蛋白溶酶抑制剂通过与纤维蛋白溶酶形成复合物而被消耗后，才观察到纤维蛋白溶酶-α2 - 巨球蛋白复合物的形成。即使在高度活化的血浆中，除非向血浆中加入外源性纤维蛋白溶酶，否则未观察到纤维蛋白溶酶-α1 - 抗胰蛋白酶复合物的形成。在血浆中的主要纤维蛋白溶酶抑制剂中，α2 - 纤维蛋白溶酶抑制剂是弥散性血管内凝血和纤维蛋白溶解患者血浆中浓度显著降低的唯一抑制剂。调节血浆纤维蛋白溶解最具反应性的抑制剂很可能是α2 - 纤维蛋白溶酶抑制剂。
